Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors after UFT/LV Chemotherapy

2Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Immune checkpoint inhibitors are mainly used for right-sided, microsatellite instability-high colorectal tumors. In this study, the effects of oral uracil–tegafur plus leucovorin (UFT/LV) chemotherapy on the gene expressions of four immunotherapy targets and the amounts of tumor-infiltrating lymphocytes (TILs) were investigated. Patients and Methods: Data of 260 patients with stage II or stage III colorectal cancer were analyzed. Gene expression and amount of TILs were evaluated using real-time reverse transcription polymerase chain reaction (CRT-PCR) assay and immunohistochemical staining, respectively. Results: Expression of CTLA4 and LAG3 in tumor tissues was significantly increased after UFT/LV chemotherapy, but only in left-sided tumors. The percentage of high-TIL, high-CD3 and high-FoxP3 patients in the UFT/LV group was significantly higher than that in the control group, only in left-sided tumors. Conclusion: The increase in TILs count, especially of CD3+ T cells and FoxP3+ regulatory T cells, after UFT/LV chemotherapy were specific to left-sided colorectal cancers.

Cite

CITATION STYLE

APA

Sadahiro, S., Suzuki, T., Tanaka, A., Okada, K., Saito, G., Miyakita, H., … Nagase, H. (2019). Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors after UFT/LV Chemotherapy. Anticancer Research, 39(4), 1997–2005. https://doi.org/10.21873/anticanres.13310

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free